CYTK
Cytokinetics, Incorporated Healthcare - Biotechnology Investor Relations →
Cytokinetics, Incorporated (CYTK) closed at $62.34 as of 2026-02-02, trading 30.4% above its 200-week moving average of $47.82. The stock is currently moving closer to the line, down from 32.4% last week. The 14-week RSI sits at 47, indicating neutral momentum.
Over the past 1088 weeks of data, CYTK has crossed below its 200-week moving average 21 times. On average, these episodes lasted 29 weeks. Historically, investors who bought CYTK at the start of these episodes saw an average one-year return of +36.1%.
With a market cap of $7.6 billion, CYTK is a mid-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. The stock trades at -14.6x book value.
Share count has increased 39.4% over three years, indicating dilution.
Over the past 20.9 years, a hypothetical investment of $100 in CYTK would have grown to $212, compared to $876 for the S&P 500. CYTK has returned 3.6% annualized vs 10.9% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Growth of $100: CYTK vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After CYTK Crosses Below the Line?
Across 21 historical episodes, buying CYTK when it crossed below its 200-week moving average produced an average return of +35.5% after 12 months (median +44.0%), compared to +14.8% for the S&P 500 over the same periods. 63% of those episodes were profitable after one year. After 24 months, the average return was +80.7% vs +31.2% for the index.
Each line shows $100 invested at the moment CYTK crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
CYTK has crossed below its 200-week MA 21 times with an average 1-year return of +36.1% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Apr 2005 | Oct 2009 | 235 | 72.7% | +9.9% | +55.3% |
| Oct 2009 | Jun 2013 | 191 | 73.1% | -43.1% | +127.4% |
| Aug 2013 | Aug 2013 | 1 | 0.2% | -55.1% | +519.1% |
| Sep 2013 | Jan 2014 | 18 | 36.3% | -55.5% | +628.3% |
| Jan 2014 | Feb 2014 | 2 | 10.7% | -10.5% | +655.6% |
| Apr 2014 | Dec 2014 | 36 | 55.7% | +58.0% | +1258.2% |
| Feb 2015 | Feb 2015 | 1 | 1.9% | +8.5% | +878.6% |
| Apr 2015 | Jun 2015 | 5 | 12.4% | +44.1% | +1003.4% |
| Jun 2015 | Jul 2015 | 2 | 5.0% | +52.1% | +881.7% |
| Jul 2015 | Aug 2015 | 1 | 0.3% | +74.0% | +875.6% |
| Feb 2016 | Mar 2016 | 4 | 7.5% | +84.2% | +894.3% |
| Nov 2017 | Jan 2018 | 7 | 14.2% | -4.3% | +720.3% |
| Jan 2018 | Jul 2018 | 22 | 20.5% | -18.3% | +620.7% |
| Jul 2018 | May 2019 | 42 | 36.5% | +26.6% | +608.4% |
| Jun 2019 | Jun 2019 | 1 | 1.4% | +124.1% | +553.5% |
| Nov 2019 | Dec 2019 | 5 | 18.0% | +106.6% | +660.2% |
| Mar 2020 | Mar 2020 | 1 | 8.0% | +160.3% | +552.8% |
| Sep 2023 | Oct 2023 | 2 | 3.4% | +77.7% | +111.6% |
| Feb 2025 | Feb 2025 | 1 | 2.3% | +45.8% | +45.8% |
| Mar 2025 | Mar 2025 | 1 | 1.7% | N/A | +43.5% |
| Mar 2025 | Sep 2025 | 23 | 32.2% | N/A | +44.3% |
| Average | 29 | — | +36.1% | — |
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of Friday close, 2026-02-02